The controversial role of ABC transporters in clinical oncology

Akina Tamaki, Caterina Ierano, Gergely Szakacs, Robert W. Robey, Susan E. Bates

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

The phenomenon of multidrug resistance in cancer is often associated with the overexpression of the ABC (ATP-binding cassette) transporters Pgp (P-glycoprotein) (ABCB1), MRP1 (multidrug resistance-associated protein 1) (ABCC1) and ABCG2 [BCRP (breast cancer resistance protein)]. Since the discovery of Pgp over 35 years ago, studies have convincingly linked ABC transporter expression to poor outcome in several cancer types, leading to the development of transporter inhibitors. Three generations of inhibitors later, we are still no closer to validating the 'Pgp hypothesis', the idea that increased chemotherapy efficacy can be achieved by inhibition of transportermediated efflux. In this chapter, we highlight the difficulties and past failures encountered in the development of clinical inhibitors of ABC transporters. We discuss the challenges that remain in our effort to exploit decades of work on ABC transporters in oncology. In learning from past mistakes, it is hoped that ABC transporters can be developed as targets for clinical intervention.

Original languageEnglish
Pages (from-to)209-232
Number of pages24
JournalEssays in Biochemistry
Volume50
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Oncology
ATP-Binding Cassette Transporters
Medical Oncology
P-Glycoprotein
Chemotherapy
Multiple Drug Resistance
Neoplasms
Learning
Breast Neoplasms
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W., & Bates, S. E. (2011). The controversial role of ABC transporters in clinical oncology. Essays in Biochemistry, 50(1), 209-232. https://doi.org/10.1042/BSE0500209

The controversial role of ABC transporters in clinical oncology. / Tamaki, Akina; Ierano, Caterina; Szakacs, Gergely; Robey, Robert W.; Bates, Susan E.

In: Essays in Biochemistry, Vol. 50, No. 1, 2011, p. 209-232.

Research output: Contribution to journalArticle

Tamaki, A, Ierano, C, Szakacs, G, Robey, RW & Bates, SE 2011, 'The controversial role of ABC transporters in clinical oncology', Essays in Biochemistry, vol. 50, no. 1, pp. 209-232. https://doi.org/10.1042/BSE0500209
Tamaki, Akina ; Ierano, Caterina ; Szakacs, Gergely ; Robey, Robert W. ; Bates, Susan E. / The controversial role of ABC transporters in clinical oncology. In: Essays in Biochemistry. 2011 ; Vol. 50, No. 1. pp. 209-232.
@article{be604d773af34b41a506219c3d94074f,
title = "The controversial role of ABC transporters in clinical oncology",
abstract = "The phenomenon of multidrug resistance in cancer is often associated with the overexpression of the ABC (ATP-binding cassette) transporters Pgp (P-glycoprotein) (ABCB1), MRP1 (multidrug resistance-associated protein 1) (ABCC1) and ABCG2 [BCRP (breast cancer resistance protein)]. Since the discovery of Pgp over 35 years ago, studies have convincingly linked ABC transporter expression to poor outcome in several cancer types, leading to the development of transporter inhibitors. Three generations of inhibitors later, we are still no closer to validating the 'Pgp hypothesis', the idea that increased chemotherapy efficacy can be achieved by inhibition of transportermediated efflux. In this chapter, we highlight the difficulties and past failures encountered in the development of clinical inhibitors of ABC transporters. We discuss the challenges that remain in our effort to exploit decades of work on ABC transporters in oncology. In learning from past mistakes, it is hoped that ABC transporters can be developed as targets for clinical intervention.",
author = "Akina Tamaki and Caterina Ierano and Gergely Szakacs and Robey, {Robert W.} and Bates, {Susan E.}",
year = "2011",
doi = "10.1042/BSE0500209",
language = "English",
volume = "50",
pages = "209--232",
journal = "Essays in Biochemistry",
issn = "0071-1365",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - The controversial role of ABC transporters in clinical oncology

AU - Tamaki, Akina

AU - Ierano, Caterina

AU - Szakacs, Gergely

AU - Robey, Robert W.

AU - Bates, Susan E.

PY - 2011

Y1 - 2011

N2 - The phenomenon of multidrug resistance in cancer is often associated with the overexpression of the ABC (ATP-binding cassette) transporters Pgp (P-glycoprotein) (ABCB1), MRP1 (multidrug resistance-associated protein 1) (ABCC1) and ABCG2 [BCRP (breast cancer resistance protein)]. Since the discovery of Pgp over 35 years ago, studies have convincingly linked ABC transporter expression to poor outcome in several cancer types, leading to the development of transporter inhibitors. Three generations of inhibitors later, we are still no closer to validating the 'Pgp hypothesis', the idea that increased chemotherapy efficacy can be achieved by inhibition of transportermediated efflux. In this chapter, we highlight the difficulties and past failures encountered in the development of clinical inhibitors of ABC transporters. We discuss the challenges that remain in our effort to exploit decades of work on ABC transporters in oncology. In learning from past mistakes, it is hoped that ABC transporters can be developed as targets for clinical intervention.

AB - The phenomenon of multidrug resistance in cancer is often associated with the overexpression of the ABC (ATP-binding cassette) transporters Pgp (P-glycoprotein) (ABCB1), MRP1 (multidrug resistance-associated protein 1) (ABCC1) and ABCG2 [BCRP (breast cancer resistance protein)]. Since the discovery of Pgp over 35 years ago, studies have convincingly linked ABC transporter expression to poor outcome in several cancer types, leading to the development of transporter inhibitors. Three generations of inhibitors later, we are still no closer to validating the 'Pgp hypothesis', the idea that increased chemotherapy efficacy can be achieved by inhibition of transportermediated efflux. In this chapter, we highlight the difficulties and past failures encountered in the development of clinical inhibitors of ABC transporters. We discuss the challenges that remain in our effort to exploit decades of work on ABC transporters in oncology. In learning from past mistakes, it is hoped that ABC transporters can be developed as targets for clinical intervention.

UR - http://www.scopus.com/inward/record.url?scp=84856282091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856282091&partnerID=8YFLogxK

U2 - 10.1042/BSE0500209

DO - 10.1042/BSE0500209

M3 - Article

C2 - 21967059

AN - SCOPUS:84856282091

VL - 50

SP - 209

EP - 232

JO - Essays in Biochemistry

JF - Essays in Biochemistry

SN - 0071-1365

IS - 1

ER -